07:00 , May 10, 2004 |  BC Week In Review  |  Company News

Immerge BioTherapeutics Inc., Infigen other research news

Researchers published in the Proceedings of the National Aca-demy of Sciences the generation of 5 GGTA1 null piglets via nuc- lear transfer cloning using fibroblasts from GGTA1 heterozygous pigs. Immerge is a joint venture between...
07:00 , Oct 13, 2003 |  BC Week In Review  |  Company News

BioTransplant, Miltenyi Biotec deal

The companies amended a June deal under which BTRN is selling its Eligix HDM cell separation systems to Miltenyi. As amended, BTRN said it will sell the systems for $175,000 plus 4-8% royalties on future...
07:00 , Jun 30, 2003 |  BC Week In Review  |  Clinical News

BioTransplant, MedImmune Inc. preclinical data

Researchers published in Blood that in a model of adult T cell leukemia, MEDI-507-treated mice survived longer than placebo mice (p<0.0001). Six-months of therapy improved survival compared to short-term therapy (p<0.0036). The partners have postponed...
07:00 , Jun 16, 2003 |  BC Week In Review  |  Clinical News

BioTransplant, Novartis preclinical data

The companies' Immerge BioTherapeutics joint venture presented data from 9 diabetic cynomolgus monkeys showing that 8 monkeys transplanted with islets from the pancreases of adult pigs or miniature swine became insulin independent and reached normal...
07:00 , Jun 9, 2003 |  BC Week In Review  |  Company News

BioTransplant, Miltenyi Biotec deal

BTRN is selling its Eligix HDM cell separation systems to Miltenyi for $450,000 plus 4%-10% royalties on future sales. The systems are used to treat B cell malignancies. BTRN, which has filed for Chapter 11,...
07:00 , May 12, 2003 |  BC Week In Review  |  Company News

Osiris management update

Osiris Therapeutics Inc. , Baltimore, Md.   Business: Gene/Cell therapy   Hired: James Embree as SVP of operations, formerly SVP of manufacturing and development at BioTransplant Corp.  ...
07:00 , Apr 28, 2003 |  BC Week In Review  |  Clinical News

Siplizumab: Phase II

BTRN partner MEDI said it plans to postpone the initiation of further trials of siplizumab in psoriasis pending the completion of a Phase II psoriasis trial of Vitaxin, MEDI's monoclonal antibody against integrin alpha(v)-beta(3). BioTransplant...
07:00 , Apr 7, 2003 |  BC Week In Review  |  Company News

BioTransplant, Catholic University of Louvain antibodies, autoimmune/inflammation, transplant news

The parties settled their licensing dispute related to a 1993 deal under which the university granted BTRN exclusive rights to develop and market BTI-322, a rodent monoclonal antibody. As settled, BTRN said it retains its...
08:00 , Mar 17, 2003 |  BioCentury  |  Tools & Techniques

Sizing up the psoriasis market

Company Compound Description Status Partner Biogen Amevive alefacept LFA-3 fusion protein Mkt Novartis Neoral cyclosporine Calcineurin inhibitor Mkt Genentech Raptiva efalizumab Anti-CD11a antibody Under review in U.S., Europe Serono; Xoma Allergan Tazorac tazarotene Oral retinoid...
08:00 , Feb 3, 2003 |  BC Week In Review  |  Company News

BioTransplant, Catholic University of Louvain deal

The parties agreed to suspend for 30 days the university's notice of termination of a 1993 deal under which the university granted BTRN exclusive rights to develop and market BTI-322, a rodent monoclonal antibody. BTRN...